New anticoagulant therapy.
The development of new anticoagulants is expanding the list of drugs that can be used to prevent and treat venous and arterial thrombosis. New parenteral anticoagulants have been developed to overcome the limitations of heparin and low-molecular-weight heparin, whereas novel orally active anticoagulants have been designed to provide more streamlined therapy than vitamin K antagonists. This review identifies the molecular targets of new anticoagulants, describes the results of clinical trials, and provides clinical perspective on the opportunities for new anticoagulants.
Linkins
Lori-Ann
LA
McMaster University and Henderson Research Center, Hamilton, Ontario, Canada L8V 1C3. llinkins@thrombosis.hhscr.org
Weitz
Jeffrey I
JI
D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D000990:Antithrombin III / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D015507:Drugs, Investigational / Q000008:administration & dosage*; D015944:Factor VIIIa / Q000037:antagonists & inhibitors; D015942:Factor VIIa / Q000037:antagonists & inhibitors; D015943:Factor Va / Q000037:antagonists & inhibitors; D006801:Humans; D008074:Lipoproteins / Q000008:administration & dosage; D013917:Thrombin / Q000037:antagonists & inhibitors; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy*
D000925:Anticoagulants; D015507:Drugs, Investigational; D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D015943:Factor Va; D015944:Factor VIIIa; D000990:Antithrombin III; D015942:Factor VIIa; D013917:Thrombin